| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
8247 Stock Overview
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products in Mainland China.
Biosino Bio-Technology and Science Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.40 |
| 52 Week High | HK$1.94 |
| 52 Week Low | HK$1.08 |
| Beta | 0.20 |
| 1 Month Change | -4.76% |
| 3 Month Change | -20.46% |
| 1 Year Change | 15.70% |
| 3 Year Change | -6.67% |
| 5 Year Change | -43.78% |
| Change since IPO | -48.62% |
Recent News & Updates
Shareholder Returns
| 8247 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.1% | 1.5% | 3.1% |
| 1Y | 15.7% | -55.7% | -21.2% |
Return vs Industry: 8247 exceeded the Hong Kong Biotechs industry which returned -55.7% over the past year.
Return vs Market: 8247 exceeded the Hong Kong Market which returned -21.2% over the past year.
Price Volatility
| 8247 volatility | |
|---|---|
| 8247 Average Weekly Movement | 1.9% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 8247 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: 8247's weekly volatility has decreased from 12% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 421 | Peng Chen | https://www.sinobio.com.cn |
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagent products in Mainland China. It offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; time-resolved fluoroimmunoassay analyzers; and flow cytometers and bio chemical analyzers. The company also provides medical and medical inspection services; produces medical instruments; and distributes immunodiagnostic products, biological reagents, and instruments.
Biosino Bio-Technology and Science Incorporation Fundamentals Summary
| 8247 fundamental statistics | |
|---|---|
| Market Cap | CN¥173.01m |
| Earnings (TTM) | -CN¥1.08m |
| Revenue (TTM) | CN¥355.89m |
0.5x
P/S Ratio-160.0x
P/E RatioIs 8247 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8247 income statement (TTM) | |
|---|---|
| Revenue | CN¥355.89m |
| Cost of Revenue | CN¥212.92m |
| Gross Profit | CN¥142.98m |
| Other Expenses | CN¥144.06m |
| Earnings | -CN¥1.08m |
Last Reported Earnings
Mar 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0075 |
| Gross Margin | 40.17% |
| Net Profit Margin | -0.30% |
| Debt/Equity Ratio | 87.0% |
How did 8247 perform over the long term?
See historical performance and comparisonValuation
Is 8247 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8247?
Other financial metrics that can be useful for relative valuation.
| What is 8247's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CN¥173.01m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 6.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 8247's PS Ratio compare to its peers?
| 8247 PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 43.8x | ||
690 Uni-Bio Science Group | 1.5x | n/a | HK$477.4m |
1228 CANbridge Pharmaceuticals | 46.5x | 51.7% | HK$1.7b |
6628 Transcenta Holding | 32.5x | 37.8% | HK$1.9b |
2256 Abbisko Cayman | 94.6x | 58.4% | HK$2.5b |
8247 Biosino Bio-Technology and Science Incorporation | 0.5x | n/a | HK$202.6m |
Price-To-Sales vs Peers: 8247 is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (43.8x).
Price to Earnings Ratio vs Industry
How does 8247's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs Industry: 8247 is good value based on its Price-To-Sales Ratio (0.5x) compared to the Hong Kong Biotechs industry average (30x)
Price to Sales Ratio vs Fair Ratio
What is 8247's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8247's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 8247 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8247 (HK$1.4) is trading below our estimate of fair value (HK$7.45)
Significantly Below Fair Value: 8247 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8247's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Biosino Bio-Technology and Science Incorporation forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
52.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosino Bio-Technology and Science Incorporation has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Biosino Bio-Technology and Science Incorporation is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Biosino Bio-Technology and Science Incorporation competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Biosino Bio-Technology and Science Incorporation performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-28.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8247 is currently unprofitable.
Growing Profit Margin: 8247 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 8247 is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.
Accelerating Growth: Unable to compare 8247's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8247 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11.3%).
Return on Equity
High ROE: 8247 has a negative Return on Equity (2.44%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Biosino Bio-Technology and Science Incorporation's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 8247's short term assets (CN¥408.1M) exceed its short term liabilities (CN¥389.0M).
Long Term Liabilities: 8247's short term assets (CN¥408.1M) exceed its long term liabilities (CN¥19.3M).
Debt to Equity History and Analysis
Debt Level: 8247's net debt to equity ratio (61.6%) is considered high.
Reducing Debt: 8247's debt to equity ratio has increased from 29.1% to 87% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 8247 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 8247 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.3% per year.
Discover healthy companies
Dividend
What is Biosino Bio-Technology and Science Incorporation current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 8247's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 8247's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8247's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8247's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 8247 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 8247 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.6yrs
Average board tenure
CEO
Peng Chen (47 yo)
0.50
Tenure
Mr. Chen Peng has been President of Biosino Bio-Technology and Science Incorporation since December 7, 2021. Mr. Chen has ample experience in corporate management chain operational management of high-tech...
Board Members
Experienced Board: 8247's board of directors are considered experienced (3.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biosino Bio-Technology and Science Incorporation's employee growth, exchange listings and data sources
Key Information
- Name: Biosino Bio-Technology and Science Incorporation
- Ticker: 8247
- Exchange: SEHK
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$202.590m
- Shares outstanding: 144.71m
- Website: https://www.sinobio.com.cn
Number of Employees
Location
- Biosino Bio-Technology and Science Incorporation
- No. 27, Chaoqian Road
- Science and Technology Industrial Park
- Beijing
- 102200
- China
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/30 00:00 |
| End of Day Share Price | 2022/06/29 00:00 |
| Earnings | 2022/03/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.